495. Upscaling of Retroviral Vector Production under GMP Guidelines to Generate High Titer Preparations for Clinical Use

High titer retroviral vector supernatant, produced in compliance with GMP, has always been a prerequisite for gene therapy purposes in clinical trials. But most vector production procedures have their limitations: the vector often leads only to low titer supernatant, only a few harvest cycles can be done and harvest volumes are often small.